EUVIMEDEUVIMED entdecken
Open Access

A model-free phase I/II dose optimization design for immunotherapy trials

Yingjie Qiu iD, Mengyi Lu, Yan Han, Wenxian Zhou, Yi Zhao, Leng Han, Yong Zang iD

Statistical Methods in Medical Research · 2025

DOI: 10.1177/09622802251340246 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistical Methods in Medical Research, 2025. Verfasst von Yingjie Qiu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA. Hauptthemen laut MEDLINE: Clinical Trials, Phase I as Topic, Immunotherapy, Clinical Trials, Phase II as Topic, Research Design. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present a model-free phase I/II clinical trial design, referred to as the UFO design, to optimize the dose of immunotherapy by jointly modeling toxicity, efficacy, and immune response outcomes. Instead of relying on complex parametric modeling approaches, we propose a model-free approach that uses the inherent correlations among different types of outcomes in immunotherapy and the constrained dose-outcome order to facilitate information sharing across different doses. This approach ensures the efficiency and transparency of the UFO design to be implemented in clinical practice. The UFO design is also extended to accommodate the delayed outcomes. It demonstrates favorable operating characteristics through simulation studies. The R Shniy app for simulation and trial implementation using the UFO design is also provided at iusccc.shinyapps.io/smartdesign .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase I as TopicImmunotherapyClinical Trials, Phase II as TopicResearch DesignHumansModels, StatisticalComputer Simulation

Stichwörter der Autor:innen

Phase I/II clinical trialsadmissible setdelayed outcomesdose optimizationimmunotherapyisotonic regressionmodel-freeutility

Autor:innen und Institutionen

  • Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Biostatistics, Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, USA.
  • Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN, USA.

ORCID-Profile: Yingjie Qiu, Yong Zang

Förderung

  • NCI NIH HHS
  • NIH

Zitieren

APA

Qiu, Y., Lu, M., Han, Y., Zhou, W., Zhao, Y., Han, L., & Zang, Y. (2025). A model-free phase I/II dose optimization design for immunotherapy trials. Statistical Methods in Medical Research. https://doi.org/10.1177/09622802251340246

Vancouver

Qiu Y, Lu M, Han Y, Zhou W, Zhao Y, Han L, et al. A model-free phase I/II dose optimization design for immunotherapy trials. Statistical Methods in Medical Research. 2025. doi:10.1177/09622802251340246

BibTeX
@article{Qiu2025,
  author = {Qiu, Yingjie and Lu, Mengyi and Han, Yan and Zhou, Wenxian and Zhao, Yi and Han, Leng and Zang, Yong},
  title = {A model-free phase I/II dose optimization design for immunotherapy trials},
  journal = {Statistical Methods in Medical Research},
  year = {2025},
  doi = {10.1177/09622802251340246}
}
Kostenlos starten →